Disease clearance – a new horizon in ulcerative colitis
Review articleGastroent Hepatol 2025; 79(5): 390–395. doi: 10.48095/ccgh2025390
SummaryLiteraturepdf Igor Šturdík, Anna Gojdičová, Samuel Majna, Jana Skubáková, Zuzana Vrablicová, Jozef Tóth, Tibor HlavatýGuselkumab in the treatment of inflammatory bowel diseases
Review articleGastroent Hepatol 2025; 79(5): 384–389. doi: 10.48095/ccgh2025384
SummaryLiteraturepdf Milan LukášAutoimmune chronic pancreatitis and idiopathic bowel disease
Review articleGastroent Hepatol 2025; 79(3): 202–206. doi: 10.48095/ccgh2025202
SummaryLiteraturepdf David Solil, Petr Dítě, Tomáš Kupka, Marie Přecechtělová, Jiří Dolina, Bohuslav KianičkaPolymorphic forms of rifaximin and clinical efficacy
Drug profileGastroent Hepatol 2025; 79(2): 131–133. doi: 10.48095/ccgh2025131
Literaturepdf Milan LukášUpdate on screening for latent tuberculosis in patients on biological therapy
Diskuzní příspěvekGastroent Hepatol 2025; 79(2): 134–135. doi: 10.48095/ccgh2025134
Literaturepdf Milan LukášIron carboxymaltose in the treatment of iron deficiency/anaemia in patients with IBD
Drug profileGastroent Hepatol 2025; 79(1): 58–64. doi: 10.48095/ccgh202558
Literaturepdf Michaela BachratáBiosimilar ustekinumab CT-P43
Drug profileGastroent Hepatol 2025; 79(1): 55–56. doi: 10.48095/ccgh202555
Literaturepdf Milan LukášResults of the DIPEX project on Crohn‘s disease and ulcerative colitis
Review articleGastroent Hepatol 2025; 79(1): 43–48. doi: 10.48095/ccgh202543
SummaryLiteraturepdf Hana Bednaříková, Kristýna GábováMirikizumab in patients with ulcerative colitis – cases from clinical practice
Gastroent Hepatol 2025; 79(1): 37–42. doi: 10.48095/ccgh202537
SummaryLiterature Milan Lukáš, Dominik Bettenworth, Viktorie ZacharováThe most common psychiatric disorders in patients with inflammatory bowel disease
Review articleGastroent Hepatol 2025; 79(1): 30–36. doi: 10.48095/ccgh202530
SummaryLiteraturepdf Petra Mináriková, Petra Matějková, Martina Hazuková, Martina Pfeiferová